Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.

NCT06883539 is registered in ClinicalTrials.gov with LaunXP Biomedical Co., Ltd. as lead sponsor.

NCT NCT06883539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06883539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.
Lead sponsor
LaunXP Biomedical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 31, 2024
Completion date
June 30, 2028
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma, pancreas cancer, rcc, renal cell cancer, solid cancers, solid tumor cancer, solid tumor malignancies, cancer, solid tumor, unspecified, adult, solid tumors refractory to standard therapy, solid tumour